Evidence map›Paper›PMID 31208030›Full record

ReviewInternational journal of molecular sciences2019

Ovarian Cancer Immunotherapy: Turning up the Heat.

Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?International journal of women's health · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eleonora GhisoniCandiolo Cancer Institute FPO/IRCCS, 10060 Candiolo (TO), and University of Torino, 10100 Turin, Italy. eleonora.ghisoni@ircc.it.
Martina ImbimboDepartment of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, 1005 Lausanne, Switzerland. martina.imbimbo@chuv.ch.
Stefan ZimmermannDepartment of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, 1005 Lausanne, Switzerland. stefan.zimmermann@chuv.ch.
Giorgio ValabregaCandiolo Cancer Institute FPO/IRCCS, 10060 Candiolo (TO), and University of Torino, 10100 Turin, Italy. giorgio.valabrega@ircc.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel therapies are urgently needed. The presence of tumor-infiltrating lymphocytes (TILs) in OC tumor microenvironment (TME) has already proved to be correlated with overall survival (OS), while immune evasion mechanisms are associated with poor prognosis. Although these data indicate that immunotherapy has a strong rationale in OC, single agent immune-checkpoints inhibitors (ICIs) have shown only modest results in this malignancy. In this review, we will discuss immune-targeting combination therapies and adoptive cell therapy (ACT), highlighting the challenges represented by these strategies, which aim at disrupting the stroma-tumor barrier to boost immune system against ovarian cancer.

Indexed as

ImmunotherapyAnimalsAntineoplastic Agents, ImmunologicalBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyFemaleHumansImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMolecular Targeted TherapyOvarian NeoplasmsT-Lymphocyte SubsetsTumor MicroenvironmentAntineoplastic Agents, ImmunologicalBiomarkers, Tumoradoptive cell therapyimmunotherapyovarian cancertumor infiltrating-lymphocytestumor microenvironment

Identifiers

PMID31208030
PMCPMC6628106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.